Dive Brief:
- Galvanize Therapeutics said Monday it has raised $130 million to support commercialization of its pulsed electric field ablation device.
- The Series D round comes six months after Galvanize received the Food and Drug Administration’s 510(k) clearance for the Aliya EX generator for surgical ablation of soft tissue.
- Galvanize will use the funding to expand commercialization of Aliya, advance another platform in chronic bronchitis and develop next-generation PEF products.
Dive Insight:
PEF devices deliver high-frequency, short-duration energy to induce programmed cell death. By slowly killing cells and preserving the extracellular matrix, PEF may cause less damage to healthy tissue than other locally delivered ablative therapies.
Galvanize received 510(k) clearance for an earlier version of Aliya in 2022. Later that year, the company merged with Gala Therapeutics and Galaxy Medical to acquire the RheOx and Centauri platforms. Having raised $100 million at the time of the merger, Galvanize reeled in a further $100 million last year.
The latest financing round follows the FDA’s clearance of an updated version of Aliya and the first commercial uses of the system. The updated system enables physicians to create ablation zones of about 20 mm in diameter, as well as the 10 mm zones supported by the older device. Supporting larger ablation zones could increase the pool of patients eligible for PEF.
Galvanize is commercializing Aliya while working to bring its RheOx platform to the U.S. market. RheOx, which launched in Europe in 2022, delivers PEF energy to the lung airways to reduce mucus-producing cells in chronic bronchitis patients.
HealthQuest Capital led the Series D round. Olympus Innovation Ventures and Braidwell invested in the company for the first time. Existing investors, including Sofinnova Partners, Norwest and Elevage Medical Technologies, also participated in the round.
Garheng Kong, HealthQuest’s founder and managing partner, is joining Galvanize’s board of directors.